Abstract
9503Background: KEYNOTE-006 (NCT01866319) established superiority of pembro over ipi in advanced melanoma. We provide 4-y outcomes, long-term data for pts who completed 2 y pembro, and data for sec...
Cite
CITATION STYLE
APA
Long, G. V., Schachter, J., Ribas, A., Arance, A. M., Grob, J.-J., Mortier, L., … Robert, C. (2018). 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. Journal of Clinical Oncology, 36(15_suppl), 9503–9503. https://doi.org/10.1200/jco.2018.36.15_suppl.9503
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free